R&D From genetic insight to Phase 3: What rare neurology require... Rare neurology is not defined by a lack of scientific opportunity or capital.
R&D GRIN Therapeutics: Seeking to address unmet needs in rare ne... Dr Bruce Leuchter, CEO of GRIN Therapeutics and Neurvati Neurosciences, discusses the companies GRIN-NDD work with pharmaphorum.
News US Treasury proposes curbs on Chinese biotech deals China has emerged as a major source of drug candidates for pharma groups, but a new proposal by the US Treasury could slam the brakes on future deals.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
